Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · capsules

Epic Peptides Lab · USA

Document number
PL-SDS-004
Revision
1.0 · 2026-10-03

AC-262536

capsules

WARNING

1Identification

Product Identifier
AC-262536
Document Number
PL-SDS-004
Catalogue Items Covered
  • Id
    8639
    Name
    AC-262 (Accadrine) 10mg Capsules
    Sku
    PL-AC262-10MG-CAP
Recommended Use
Laboratory research use by trained personnel.
Restrictions On Use
Not for human or veterinary use.
Supplier / Distributor
Epic Peptides Lab, USA
Telephone
+1 (787) 468-5291
Email
info@epicpeptideslab.com

2Hazard(s) identification

Classification
  • Reproductive toxicity — Category 2 — H361
Label Elements
Pictograms
  • GHS08
Signal
Warning
Hazard statements
  • H361 Suspected of damaging fertility or the unborn child.
Precautionary statements
  • P201 Obtain special instructions before use.
  • P202 Do not handle until all safety precautions have been read and understood.
  • P280 Wear protective gloves, protective clothing and eye protection.
  • P308+P313 IF exposed or concerned: Get medical advice/attention.
  • P405 Store locked up.
  • P501 Dispose of contents and container to an approved waste disposal plant in accordance with local, state and federal regulations.
Signal Word
Warning
Other Hazards
No data available.

3Composition / information on ingredients

Description
Hard gelatin capsules containing the active substance blended with microcrystalline cellulose, packed in a sealed bottle.
Composition
  • Name
    AC-262536
    Full
    AC-262536 (Accadrine), selective androgen receptor modulator
    Cas
    870888-46-3
    Formula
    C18H18N2O
    Conc
    2.5% w/w of capsule contents (nominal)
    Qty
    10 mg per capsule
    Hazards
    • Reproductive toxicity — Category 2 — H361
  • Name
    Microcrystalline cellulose
    Full
    Microcrystalline cellulose (capsule filler)
    Cas
    9004-34-6
    Formula
    (C6H10O5)n
    Conc
    balance of capsule contents
  • Name
    Gelatin
    Full
    Gelatin (capsule shell)
    Cas
    9000-70-8
    Conc
    capsule shell

4First-aid measures

First Aid Measures
Inhalation
Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin
Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes
Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion
Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.
General
If exposed or concerned, get medical advice. Show this safety data sheet to the doctor. Pregnant or nursing laboratory staff should avoid exposure.
Most Important Symptoms And Effects
No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.
Likely Routes Of Exposure
Ingestion; inhalation of dust and skin/eye contact if capsules are opened.

5Fire-fighting measures

Fire Fighting Information
Combustible organic solid; capsule contents may form combustible dust if dispersed in bulk.

6Accidental release measures

Spill And Clean Up Procedures
Collect intact capsules. Dampen any spilled powder with water, wipe up with absorbent material and place in a sealed container for disposal.

7Handling and storage

Safe Handling
Do not open or crush capsules unless required for an experiment; if capsule contents are handled as a powder, avoid generating dust and weigh inside a ventilated enclosure. Wash hands after handling.
Safe Storage
Store at room temperature (15–25 °C) in the tightly closed original container, dry and protected from light.
Storage Temperature
15–25 °C, dry, protected from light
Incompatible Materials
Strong oxidizing agents (Cayman)

8Exposure controls / personal protection

Occupational Exposure Limits
  • Microcrystalline cellulose: OSHA PEL 15 mg/m³ (total dust), 5 mg/m³ (respirable fraction); ACGIH TLV 10 mg/m³ (as cellulose).
  • No occupational exposure limits have been established for the active ingredient(s).
Exposure Controls And PPE
No data available.

9Physical and chemical properties

Physical State
Solid
Appearance
Hard gelatin capsules containing a white to off-white powder
Properties
Odor
Characteristic (odor threshold not determined)
Ph
Not applicable (solid)
Melting
Undetermined (Cayman)
Boiling
Undetermined
Flash
Not applicable (non-flammable solid); combustible organic material
Vapour
Negligible (solid)
Density
No data available (bulk density of lyophilized cake is low)
Solubility
DMSO: soluble (Cayman); water solubility not determined
Logp
No data available
Decomp
No data available; peptides decompose above about 200 °C
Other
Molecular formula C18H18N2O, MW 278.4; product is not flammable; density not determined (Cayman SDS)

10Stability and reactivity

Stability And Reactivity
Reactivity
No dangerous reactions known; no decomposition if used according to specifications (Cayman)
Incompatible
Strong oxidizing agents (Cayman)
Decomposition
Carbon oxides, nitrogen oxides (Cayman)
Conditions To Avoid
No further relevant information available (Cayman); store at -20 °C per Cayman catalogue
Conditions To Avoid
No data available.
Incompatible Materials
No data available.

11Toxicological information

Toxicological Information
  • Acute toxicity, oral

    No data available (no LD50 in Cayman SDS)

  • Acute toxicity, dermal

    No data available

  • Acute toxicity, inhalation

    No data available

  • Skin corrosion/irritation

    No irritant effect (Cayman)

  • Serious eye damage/irritation

    No irritating effect (Cayman)

  • Respiratory or skin sensitisation

    No sensitizing effects known (Cayman)

  • Germ cell mutagenicity

    No data available

  • Carcinogenicity

    Not listed by IARC, NTP or OSHA (Cayman)

  • Reproductive toxicity

    No data available in supplier SDS; see notes (SARM class concern)

  • STOT, single exposure

    No data available

  • STOT, repeated exposure

    No data available

  • Aspiration hazard

    No data available

Routes Of Exposure
Ingestion; inhalation of dust and skin/eye contact if capsules are opened.
Symptoms
No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information
Cayman: 'Water hazard class 1 (Self-assessment): slightly hazardous for water'; do not allow undiluted product or large quantities to reach ground water, water course or sewage system. No aquatic toxicity data.

13Disposal considerations

Disposal Guidance
No data available.

14Transport information

Transport Classification
Note
Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information
Tsca
Not listed (Cayman: 'Substance is not listed')
Carcinogen Listings
Not listed by IARC, NTP, OSHA, EPA, NIOSH-Ca; not on California Prop 65 (Cayman)
Dea
Not scheduled
Other
WADA: SARMs are prohibited at all times under class S1.2 'Other Anabolic Agents' (remark only). FDA has issued consumer warnings on SARMs (liver toxicity, cardiovascular risk) - remark only. Not an approved drug anywhere.
Carcinogen Listings
No data available.

16Other information

Revision
October 3, 2026
Sources Consulted
  • Cayman Chemical
  • LookChem
  • Spectrum Chemical
  • Sigachi Industries
  • Parchem
  • Fisher Scientific / Acros Organics
  • Electron Microscopy Sciences
Confidence
high
Additional Information
  • Selective androgen receptor modulator (SARM). No supplier SDS assigns a reproductive classification, but SARMs act on the androgen receptor, suppress gonadotropins and spermatogenesis in animal and human studies and are prohibited at all times under WADA class S1.2. PrymaLab therefore self-classifies the substance as Reproductive toxicity Category 2 (H361) by expert judgement.
Back to SDS list
JOIN THE Epic Peptides Lab
Exclusive access for verified researchers only.

Enter your details to access our catalog, COA library,
and research compound database.

By submitting you agree to receive email communications from Epic Peptides Lab You can unsubscribe at any time. All products for in vitro research use only.

15% off any order

Restock alerts, new compounds and fresh lab results.
We’ll email your code straight away – 15% off, one-time use.

Research updates only. Unsubscribe any time.